1:00 – 1:05 PM

Welcome & Market Overview

Presented By:
Uday Devgan, MD - Devgan Eye Surgery/Clinical Professor - UCLA

1:05 – 2:15 PM

Company Showcase

Orasis Pharmaceuticals | Elad Kedar - CEO
LensGen | Sumit Garg, MD - Vice Chair of Clinical Ophthalmology, Medical Director, & Associate Professor - Gavin Herbert Eye Institute - University of California, Irvine
Visus Therapeutics | Ben Bergo - CEO
Omega Ophthalmics | Gary Wortz, MD - Co-Founder & Chief Medical Officer
Allotex | Michael Mrochen - President
Eyenovia | David Wirta, MD - Medical Director - Eye Research Foundation
Ocuphire Pharma | Mina Sooch - CEO
Kedalion Therapeutics | Mark Blumenkranz, MD - Chairman, CEO & Co-Founder
Yolia Health | Alberto Osio - CEO & Co-Founder

2:15 – 2:45 PM

Presbyopia Outlook Panel - Clinical Perspective

Kendall Donaldson, MD, Medical Director - Bascom Palmer Eye Institute
John Hovanesian, MD - Harvard Eye Associates
Thomas John, MD, Clinical Associate Professor - Loyola University at Chicago
Gary Wortz, MD - Commonwealth Eye Surgery

Moderated By:
Uday Devgan, MD - Devgan Eye Surgery/Clinical Professor - UCLA

2:45 – 3:30 PM

Presbyopia Outlook Panel - Industry Perspective

Tim Clover, CEO - Rayner
Glen Curran, VP, Anterior Segment - Allergan
Heather Floyd, PhD, Global Program Head for Early Programs in Ophthalmology - Novartis
Robert Kissling, MD, VP, Medical Affairs - Bausch + Lomb
Alex Long, Global Head, Intraocular Lenses - Alcon
MK Raheja, Head, Surgical Vision R&D - Johnson & Johnson Vision

Moderated By:
Mitchell Jackson, MD - Past President - Cedars Aspens / Founder & CEO - Jacksoneye

3:30 – 4:30 PM

Virtual Networking


Silver Sponsors


Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.

Promedica International

Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. We have successfully been providing exceptional value to our clients for over 30 years in clinical trial project management, site recruitment and management, clinical study monitoring, data management, biostatistics, medical writing and GCP auditing.

Bronze Sponsors


Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. Eyenovia recently submitted a US FDA NDA for MydCombi™, its product candidate for mydriasis.”

Occuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 2 and Phase 3 trials. For more information, please visit

Orasis Pharmaceuticals

Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical company focused on developing an innovative eye drop for the treatment of presbyopia symptoms. Promising results from a well powered Phase 2b study have paved an informed path for Orasis to advance their product candidate through successful initiation of Phase 3 studies, NEAR-1 and NEAR-2. Orasis’ differentiated formulation with an optimal balance between efficacy, safety and comfort, along with a proven commercialization strategy in place, positions the company as an emerging leader in the presbyopia space. Follow us on LinkedIn to learn more.

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates. For more information, visit: and follow us on Twitter (@VisusTx) and on LinkedIn.